Point72 Asia (Singapore) Pte. Ltd. Zentalis Pharmaceuticals, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 3,392 shares of ZNTL stock, worth $11,804. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,392Holding current value
$11,804% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
76.3MCall Options Held
68.2KPut Options Held
2.3K-
Matrix Capital Management Company, LP Waltham, MA14MShares$48.6 Million2.04% of portfolio
-
Eventide Asset Management, LLC Boston, MA11.6MShares$40.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY4.65MShares$16.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.4MShares$15.3 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.85MShares$13.4 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $198M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...